Let me give you the punch line up front: 69% of the treatments currently in human trials have been funded by JDRF. (And the number is 86% for the later phase trials!) This is an amazing impact; one that any non-profit should be proud of.
Cures in Phase-III Human Trials
Summary: there are 4, and all of the treatments have been funded by JDRF.
- GAD65 (several different studies)
- TolerRx's CD3 (several different studies)
- MacroGenics's CD3 (several different studies)
Summary: there are 10, and 8 of them have been funded by JDRF, either directly or indirectly through ITN. Here are the treatments that have been funded by JDRF:
- MMF/DZG by Skyler
- PROCHYMAL by Osiris Therapeutics
- Rituximab by Pescovitz at Indiana
- Thymoglobulin (also known as ATG) by Gitelman
- Abatacept by Orban at Joslin Diabetes Center
- Umbilical Cord Blood Infusion by Haller at University of Florida
- Exsulin (previously INGAP) by Exsulin
- Kineret / Anakinra by Mandrup-Poulsen at Steno Diabetes Center
- Atorvastatin (Lipitor) by Willi at Children's Hospital of Philadelphia
- Brod at University of Texas-Health Science Center
Cures in Phase-I Human Trials
Summary: there are 12, and 6 of the are funded by JDRF and 6 are not. Here is the list funded by JDRF:
- BHT 3021 by Bayhill Theraputics
- Trucco at Children’s Hospital of Pittsburgh
- IBC-VS01 by Orban at Joslin Diabetes Center
- CGSF by Haller at University of Florida [*]
- Proleukin and Rapamune by Greenbaum at Benaroya Research Institute
- Lisofylline by DiaKine
- ATG and autotransplant by Burt at University of Sao Paulo
- Diabecell by Living Cell Technologies
- NI-0401 by NovImmune
- Etanercept (ENBREL) by Quattrin at University at Buffalo School of Medicine
- CGSF and autotransplant by Esmatjes at Hospital Clinic of Barcelona [*]
- Pioglitazone by Wilson at Stony Brook [*]
Summary of all Trials
26 in total
8 not funded by JDRF
So 68% of the human trials currently underway are funded (either directly or indirectly) by JDRF. Everyone who donates to JDRF should be proud of this huge impact; and everyone who works for JDRF or volunteers for it, should be doubly proud.
It is important to remember, however, that although there are four treatments in Phase-III trials, we are not close to a cure for established type-1 diabetes. All of the clinical trials in Phase-III and Phase-II are targeted at honeymoon type-1 diabetes; none at established cases. Even with that restriction. None of the treatments in Phase-III trials resulted in cures during their Phase-II trials. They all extended or increased the honeymoon phase in some way.
We have a long way to go, and that is where JDRF comes in.
Compared to Last Year
In 2008 there were 3 treatments in Phase-III trials, in 2009 there are 4 (growth of 33%).
In 2008 there were 5 treatments in Phase-II trials, in 2009 there are 10 (growth of 100%).
In 2008 there were 10 treatments in Phase-I trials, in 2009 there are 12 (growth of 20%).
I do think that a little of this "growth" is because I have gotten better at finding clinical trials, so last year I missed some trials which I'm not missing this year. But I also think that most of the growth is real. There really are more clinical trials going on now.
- I give an organization credit for funding a cure if it funded that cure at any point in it's development cycle.
- I use the term "US Gov" for all the different branches and organizations within the United States of America's federal govenment (so includes NIDDK, NIAID, NICHD, etc.)
- The ITN (Immune Tolerance Network) has JDRF as a major funder, so I count ITN as indirect JDRF funding.
- I have made no attempt to find out how much funding different organizations gave to different research. This would be next to impossible for long research programs, anyway.
- Funding of research is not my primary interest, so I don't spend a lot of time tracking down details in this area. I might be wrong on details.
- I don't work for the US Gov, JDRF, or any of the other organizations discussed here. I'm not a member of JDRF or any of the other organizations discussed here. I do own stock in several of the companies discussed here.